In breast cancer, CSCs can emerge after treatment of HER2-amplified tumors, a process mediated by IL-6 signaling that operates in an autocrine fashion to induce a CSC phenotype in response to HER2 inhibition [26], similar to the effect of notch signaling in survival and proliferation of CSCs [9,27]. This evidence concerns the gene ERBB2 and breast carcinoma.